However, a recent Phase III clinical trial of anti-CD47 antibody, magrolimab, for acute myeloid leukemia (AML) with TP53 mutation or high-risk myelodysplastic syndromes (MDS) failed to demonstrate a survival benefit. This evidence concerns the gene TP53 and acute myeloid leukemia.